Veralto Corporation (VLTO), a prominent bio-tech company, has displayed a persuasive performance over the past year, as its stock price rose 15%. The just-announced Q4 earnings beat revenue estimates, and the EPS outperformed expectations, demonstrating robust growth. Insider selling was reported, but hedge funds still consider it a top spin-off stock for investment. The acquisition of AQUAFIDES, a step taken for dominance in the European UV Treatment Market, and mulls acquisition of Austria-based Aquafides for $20M can be seen as strategic moves by the corporation. This strategy, along with investment in Axine Water Technologies, suggests a strong commitment to clean tech solutions. Importantly, they've announced regular quarterly dividends, indicating a solid cash flow status. The full-year 2024 earnings forecast looks promising with guidance set at core sales growth in the low-to-mid single-digits and EPS between $3.60 and $3.70 hinting at an optimistic future outlook.
Veralto Corporation VLTO News Analytics from Wed, 08 Feb 2023 08:00:00 GMT to Sat, 01 Mar 2025 04:13:49 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -2
